S1 File - by Kimesh Loganathan Naidoo (19697486)

“…Of the 45 015 admissions analysed, 1237(2·75%) demised with significant decreases in admissions during all the lockdown levels, with the most significant mean monthly decrease of 450(95%, CI = 657·3, -244·3) p<0·001 in level 5 (the most severe) lockdown. …”

Role of YAP/TAZ in FAT1-regulated HNSCC growth. by Rui Li (4631)

Box plot of queens and males in the young colony (left) and old colony (right) A-B compares the queens and males distribution in the young and old colonies, respectively. by Moïse Pierre Exélis (21578515)

Restoration of <i>S</i>. Paratyphi A L O-ag reduces VL O-ag production and impacts IgM binding. by Fermin E. Guerra (6084545)

The phosphorylation of Mas receptor and its induced-effects in <i>hGRK4</i> <i>γ</i> WT and 142V transgenic mice. by Lin Chen (54305)

FAT1 and MIB2 control tumor growth <i>in vivo.</i> by Rui Li (4631)

TRIM56 promotes the ubiquitination and proteasomal degradation of CVB3 3D. by Yao Wang (102387)

Vps34 orchestrates Treg function in vivo. by Erienne G. Norton (9612079)

<i>rfbV</i> gene triplication in S. Paratyphi A increases VL O-ag production and reduces C3b deposition. by Fermin E. Guerra (6084545)

“…Statistical analysis was performed by one sample t test with a hypothetical value of 1.0, with P values in red indicating statistical significance as P < 0.05. Column bars represent the mean with error bars showing standard deviation. …”

Targeting of Vps34 reduces B16F10 tumor growth and working model for Vps34-dependent regulation of eTreg transitional heterogeneity and maintenance. by Erienne G. Norton (9612079)

Loss of Vps34 reduces Treg suppressive function and is associated with the development of type-I-dominant inflammatory disease. by Erienne G. Norton (9612079)

Vps34 supports Treg maintenance in lymphoid and non-lymphoid tissues. by Erienne G. Norton (9612079)

“…(<b>I</b>) Quantification of Bim/Mcl1 (left) and Bim/Bcl2 (right) ratios (based on gMFIs) from TCRβ⁺CD4⁺Foxp3⁺CD44^lowCD62L^high cTregs or TCRβ⁺CD4⁺Foxp3⁺CD44^highCD62L^low eTregs derived from the spleen of control (<i>n</i> = 19) or <i>Foxp3</i>^Cre<i>Pik3c3</i>^fl/fl (<i>n</i> = 17) mixed BM chimera mice. gMFI, geometric mean fluorescence intensity. Data are shown as mean ± s.e.m. …”

Atg14 does not contribute to terminal eTreg generation during perinatal life. by Erienne G. Norton (9612079)

Chromatin accessibility analysis of perinatal Vps34-deficient Tregs. by Erienne G. Norton (9612079)

“…Relative (normalized to average control in each experiment) fold-change comparisons between genotypes in each cell type are shown in bold (<b>A</b>, <b>B</b>). Data are shown as mean ±  s.e.m. (<b>A</b>, <b>B</b>). Two-tailed Student <i>t</i> test (<b>A</b>, <b>B</b>, <b>I</b>), Benjamini–Hochberg test (<b>C</b>), Wilcoxon rank-sum test (<b>G</b>), Fisher’s exact tes<i>t</i> (<b>H</b>), or binomial test (<b>J</b>); NS, not significant. …”

Atg14 plays a cell-intrinsic role in orchestrating eTreg survival but not terminal differentiation. by Erienne G. Norton (9612079)

“…Jun/Fos transcription factors with predicted decreased activity in Atg14-deficient versus control eTregs are labeled. …”

Analysis of Tregs from perinatal mice and mixed BM chimeras for transitional and terminal eTreg states. by Erienne G. Norton (9612079)

Vps34 orchestrates transcriptional and epigenetic remodeling events corresponding to terminal eTreg differentiation during perinatal life. by Erienne G. Norton (9612079)

“…See also <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.3003074#pbio.3003074.s017" target="_blank">S9 Table</a>. Data are shown as mean ± s.e.m. (<b>D</b>). Wilcoxon rank-sum test (<b>A</b>, <b>B</b>; <b>J</b>, right), Benjamini–Hochbert test (<b>C</b>), two-tailed Student <i>t</i> test (<b>D</b>, <b>I</b>), Fisher’s exact test (<b>F</b>–<b>H</b>), or bionomial test (<b>J</b>, left); NS, not significant. …”

Uvrag in Tregs is dispensable for establishment of immune tolerance and eTreg accumulation. by Erienne G. Norton (9612079)

Targeting of Vps34 or Atg14, but not Uvrag, in Tregs reduces tumor growth in mouse models. by Erienne G. Norton (9612079)

Atg14 deficiency in Tregs induces a type-I-dominant lymphoproliferative disease and cell-intrinsic reductions in eTregs. by Erienne G. Norton (9612079)